Research programme: neurodegenerative disorder therapeutics - NosciraAlternative Names: NP-17; NP-901; NPM-05 family
Latest Information Update: 07 Mar 2013
At a glance
- Originator Neuropharma
- Developer Noscira
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Amyloid precursor protein secretase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease; Neuroprotection